News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
iBio, Inc. Announces Successful Production of Critical Hookworm Vaccine Antigen
May 26, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
iBio, Inc. (NYSE AMEX: IBIO) today announced that its proprietary iBioLaunch™ Platform successfully expressed the hookworm-derived molecule known as NaAPR1M-74, which will be evaluated as a potential vaccine candidate for human hookworm disease.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
MORE ON THIS TOPIC
Gene therapy
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
November 7, 2025
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
November 6, 2025
·
3 min read
·
Heather McKenzie
IN PARTNERSHIP WITH PII
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
November 6, 2025
·
1 min read
·
BioSpace Insights
FDA
Webinar: FDA in 2025: Navigating an Uncertain Regulatory Future
November 5, 2025
·
1 min read
·
Jef Akst
